DFDA

L-Glutamine (Endari)

Treatment for Sickle Cell Disorders

Typical Dosage: 10-30 g daily, based on weight

Effectiveness
55%
Safety Score
85%
Clinical Trials
7
Participants
400

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe
Treatment Details
Dosage Range
10-30 g daily, based on weight
Time to Effect
3-6 months
Treatment Duration
Lifetime
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
9(Treat 9 patients to see 1 additional successful outcome)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$35,000
Monitoring:$200
Side Effect Mgmt:$100
Total Annual:$35,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$400,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$141,200
L-Glutamine (Endari) Outcomes

for Sickle Cell Disorders

Efficacy Outcomes
Overall Effectiveness
+55%
Response Rate
+25%
Common Side Effects
Nausea
+8%
Headache
+7%
Abdominal pain
+5%

Sources:

sicklecellanemianews.com
checkrare.com
fda.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
5 completed trials for L-Glutamine (Endari) in Sickle Cell Disorders

Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients

NCT04684381COMPLETEDPHASE4
View Study
13 participants
INTERVENTIONAL
Cincinnati, United States
Started: Jan 4, 2021

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

NCT00125788COMPLETEDPHASE2
View Study
70 participants
INTERVENTIONAL
Bellflower, United States +4 more
Started: Mar 1, 2004

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

NCT01179217COMPLETEDPHASE3
View Study
230 participants
INTERVENTIONAL
Mobile, United States +30 more
Started: May 1, 2010

Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

NCT01048905COMPLETEDPHASE2
View Study
13 participants
INTERVENTIONAL
Oakland, United States
Started: Mar 1, 2009

Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients

NCT05371184COMPLETEDPHASE4
View Study
60 participants
INTERVENTIONAL
Cairo, Egypt +1 more
Started: Jan 4, 2022